Startup Seeks to Expand Primate Breeding in U.S.

Safer Human Medicine faces local opposition while trying to address a national shortage of research monkeys.

Updated on Oct. 28, 2026 in Healthcare

Stainless steel ventilation unit inside a clean, sterile laboratory, reflecting the industrial nature of biological research facilities. — Safer Human Medicine is working to establish domestic facilities to breed 30,000 macaque monkeys to stabilize the research supply chain. AI Illustration. Upload story photo >

Live Poll

Do you support the use of animal testing to advance medical research?

Safer Human Medicine, which received a $20 million investment from Joe Lonsdale's 8VC in 2023, is working to establish facilities to breed 30,000 macaque monkeys. The company aims to stabilize the supply chain for drug and research laboratories following significant export restrictions from abroad.

Why it matters

The firm aims to address a critical domestic supply shortage of primates needed for medical research, exacerbated by export halts and regulatory crackdowns on smuggling. Building a reliable U.S. source is intended to meet projected demand as research labs navigate a difficult global market.

Safer Human Medicine has raised $28 million in total capital, including a $20 million investment from 8VC. The company previously pledged to invest $270 million into a facility project in Georgia, which intended to support 263 new jobs.

The players

Joe Lonsdale

He is an American entrepreneur and venture capitalist who serves as the founder of the investment firm 8VC.

Safer Human Medicine

The company is a private startup dedicated to breeding and supplying macaque monkeys for use in medical and drug research.

8VC

This is a venture capital firm that manages approximately $6 billion in assets and invests in various technology and life sciences startups.

The details

Safer Human Medicine currently operates a facility in LaBelle, Florida, while challenging a decision by a Georgia development authority to revoke an incentive package. The company utilizes these facilities to house and quarantine macaques for essential medical research supply chains.

2020: China halted primate exports to U.S. laboratories.
2022: U.S. law removed the requirement for mandatory animal drug testing.
Late 2022: The U.S. Justice Department charged a monkey smuggling ring.
2023: 8VC invested $20 million in Safer Human Medicine.
February 2024: A Georgia development authority revoked an incentive package for the company.

Market Landscape

The expansion of domestic monkey breeding reflects a strategic shift to replace formerly reliable international supply chains that collapsed after 2020. This move positions the firm to capture significant market share as medical researchers seek to avoid the volatility and legal risks of importing research animals.

While the project has little direct effect on individual consumer retail budgets, the development of domestic research primate supplies could influence the cost and speed of future drug development. Increased supply chain security for labs may lead to more predictable timelines for testing new medical treatments.

The takeaway

The effort to localize primate breeding highlights the ongoing logistical challenges in medical research following global export disruptions. As the industry evolves, investors and researchers remain focused on securing a stable, legal, and ethical domestic supply of necessary research animals.